title: Establishment of a novel extracorporeal bowel model to study luminal approaches to treat inflammatory bowel disease.
abstract: We have established an extracorporeal bowel model system for the analysis of early events in inflammatory bowel disease (IBD) and therapeutic applications. This model consists of an intestinal segment that is cannulated and perfused in situ, allowing the investigation of cellular responses of apical mucosa cells on luminal applied substances. Short-term treatment with iodoacetamide mimicked experimental intestinal inflammation in IBD, as indicated by histological alterations such as hemorrhage, hyperemia and loss of regular crypt architecture, as well as enhanced expression of cytokines (e.g. IL-6, IL-10 and MCP-1) compared with control segments perfused with media. Perfusion of therapeutic agents (e.g. dexamethasone or Mutaflor) in the small intestine segment significantly reduced the features of early inflammation that are induced by iodoacetamide. Moreover, similar data were obtained for Resormin(®), a montmorillonite-illite mixed-layer mineral (smectite), indicating that smectites might be a newly identified therapeutic option for IBD. In summary, this model could provide novel insights into epithelial injury as well as genesis of IBD and, therefore, be useful in testing the therapeutic potential of compounds for IBD therapy.
authors.affiliation: Division of Gastroenterology, Department of Medicine II, University of Rostock, 18057 Rostock, Germany.
authors.forename: Anne
authors.initials: A
authors.lastname: Breitrück
authors.forename: Gisela
authors.initials: G
authors.lastname: Sparmann
authors.forename: Steffen
authors.initials: S
authors.lastname: Mitzner
authors.forename: Claus
authors.initials: C
authors.lastname: Kerkhoff
mesh_terms: D000818:Animals; D016207:Cytokines / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008954:Models, Biological; D051381:Rats; D011917:Rats, Inbred Lew; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D016207:Cytokines
references.citation: Lab Invest. 1993 Aug;69(2):238-49
references.pmid: 8350599
references.citation: Am J Physiol. 1998 Jan;274(1):G203-9
references.pmid: 9458791
references.citation: Gut. 1997 Sep;41(3):358-65
references.pmid: 9378392
references.citation: Expert Opin Pharmacother. 2009 Jun;10(9):1449-60
references.pmid: 19445560
references.citation: Dev Pharmacol Ther. 1989;13(1):46-50
references.pmid: 2673691
references.citation: Prostaglandins Other Lipid Mediat. 2006 Mar;79(1-2):43-52
references.pmid: 16516809
references.citation: Cell Res. 2010 Mar;20(3):288-98
references.pmid: 20101265
references.citation: Front Biosci. 2008 Jan 01;13:1654-64
references.pmid: 17981657
references.citation: Lab Invest. 2012 Jan;92(1):9-21
references.pmid: 21894149
references.citation: Aliment Pharmacol Ther. 2007 Aug 1;26(3):313-29
references.pmid: 17635367
references.citation: Digestion. 2012;86 Suppl 1:6-10
references.pmid: 23051720
references.citation: Toxicology. 2003 Mar 3;184(2-3):125-33
references.pmid: 12499115
references.citation: Gastroenterol Clin North Am. 1992 Jun;21(2):451-502
references.pmid: 1512051
references.citation: J Exp Med. 1998 Nov 16;188(10):1929-39
references.pmid: 9815270
references.citation: Gut. 2009 Mar;58(3):379-87
references.pmid: 18852260
references.citation: J Pharm Pharmacol. 2001 Jul;53(7):1007-13
references.pmid: 11480535
references.citation: Gut. 1993 Jan;34(1):51-5
references.pmid: 8432452
references.citation: Pathobiology. 2002-2003;70(3):121-30
references.pmid: 12571415
references.citation: Aliment Pharmacol Ther. 2006 Jan 15;23(2):217-27
references.pmid: 16393300
references.citation: Cancer Cell. 2009 Feb 3;15(2):103-13
references.pmid: 19185845
references.citation: Lab Invest. 1997 Mar;76(3):319-27
references.pmid: 9121115
references.citation: Gastroenterology. 1990 Mar;98(3):694-702
references.pmid: 1688816
references.citation: Aliment Pharmacol Ther. 2003 Jul 1;18(1):45-56
references.pmid: 12848625
references.citation: Gut. 2010 Feb;59(2):186-96
references.pmid: 19074180
references.citation: Pharmacol Rev. 2003 Jun;55(2):241-69
references.pmid: 12773629
references.citation: J Dig Dis. 2007 Nov;8(4):171-8
references.pmid: 17970872
references.citation: Br J Pharmacol. 2004 Mar;141(6):951-60
references.pmid: 14993105
references.citation: Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:11-8
references.pmid: 16961738
references.citation: N Engl J Med. 2002 Aug 8;347(6):417-29
references.pmid: 12167685
references.citation: J Physiol. 2003 Aug 1;550(Pt 3):863-71
references.pmid: 12794180
references.citation: Jpn J Pharmacol. 1997 Apr;73(4):299-309
references.pmid: 9165366
references.citation: Pharmacol Rep. 2011;63(3):629-42
references.pmid: 21857074
references.citation: Indian J Pharm Sci. 2010 Sep;72(5):625-9
references.pmid: 21694996
references.citation: Gastroenterol Res Pract. 2011;2011:783196
references.pmid: 21760777
references.citation: Cell Host Microbe. 2007 Dec 13;2(6):371-82
references.pmid: 18078689
references.citation: J Exp Med. 1995 Nov 1;182(5):1281-90
references.pmid: 7595199